This site uses cookies. By continuing to use this site you agree to our use of cookies. To find out more, see our Privacy and Cookies policy.
Skip to the content

IOP A community website from IOP Publishing

Recently in AAPM Annual Meeting 2007 Category

Bad boys

| | Comments (22)

10:05 Wednesday CT: When I saw Radiological Imaging Technology's (RIT) latest advertising poster I had to go and find out more. It features leather clad men and a very hot custom motorcycle – not the usual marketing tactic of QA software vendors. Apparently, however, if you're a medical physicist then it's not only the motorcycle that's hot. RIT has just launched version 5 (V5) of its QA software package RIT113, and according to vice president of marketing Ellen Ritt, the new features are getting physicists at the show "very excited".

Physicists aren't usually the most excitable of people, so what's all the fuss about? As well as many new time-saving features, V5 includes a "unique correction algorithm" that can be used to get more information from radiochromic film. Hospital physicists are under increasing pressure these days to find an alternative to the wet-film techniques traditionally used for many QA tasks. Wet film provides good-quality images, but processing it is costly and time-consuming. As a result, many hospitals are switching to radiochromic film.

Radiochromic film - much like Polaroid film - is very convenient because it doesn't need to be processed. The drawback is that you can't achieve the same level of image quality as you can with wet film. The new V5 software, however, has an image analysis tool that RIT claims can correct for this, allowing QA physicists to get as much information from radiochromic film images as they could get from wet film images. If it lives up to the marketing hype, then it sounds like this could make a lot of hospital physicists' jobs much easier.

RIT is inviting AAPM attendees to "test drive" V5 at its booth, so go along and see if it really is all it's cracked up to be. And if you're lucky staff will even give you some free (temporary) tattoos to complete the bad-boy image. Sadly, however, there is no sign of a prize draw or raffle to win the motorcycle.

The great IGRT debate

| | Comments (32)

06.57 Wednesday CT: It's not often that a clinical technology decision is made on the basis of who can make the most noise. Well, perhaps sometimes it is - but certainly never when that noise is being made by plastic clapping hands wielded by an audience of slightly overexcited medical physicists (see picture).

The clinical decision in question was which of the numerous technologies employed for image-guided radiation therapy (IGRT) is most likely to succeed. In a session entitled "The Great Debate: The Future of IGRT Is...", five distinguished speakers presented opening arguments for megavoltage (MV) and kilovoltage (kV) CT, ultrasound-based hybrids, MRI guidance and 3D deformable image registration. As for the audience: well we got to decide the winner via a show of (clapping plastic) hands.

In what was possibly the most entertaining - and certainly the most raucous - scientific conference session that I've ever attended, Marc Kessler (a professor of radiation oncology at University of Michigan Medical School, Ann Arbor, MI) demonstrated a novel, if somewhat unnerving, method of timekeeping. Any speaker running over their allocated time slot found themselves the target of Kessler's Nerf gun (which fires Styrofoam "bullets"). Kessler certainly seemed to be enjoying himself anyway.

Round one of the debate gave each speaker just six minutes to introduce their case. First up was Jean Pouliot of the University of California, San Francisco (San Francisco, CA) who described the advantages of cone-beam and fan-beam MV CT. "It's a long-term dream to turn the imaging machine into the treatment machine," he said. "[With MV CT], the treatment beam is the imaging beam - you treat what you see."

Pouliot rebuffed the claims from other panel members that the technique delivers too high a dose and doesn't give good enough image quality, pointing out that image quality has rapidly increased over the last five years, and continues to do so. "It provides equivalent alignment precision to kV cone-beam CT," he claimed, adding that the dose can be comparable too.

The second speaker to take the stand (and brave the Nerf gun) was Jan-Jakob Sonke of the Netherlands Cancer Institute in Amsterdam. Sonke presented the case for kV cone-beam CT and discussed the latest technology advances, such as 4D guidance to account for respiratory motion. Sonke told the audience how - following a quick vendor survey at the trade show - he concluded that kV CT represents the lowest cost option of all the proposed methods in the debate.

Next up, Wolfgang Tomé of the University of Wisconsin-Madison (Madison, WI) touted the idea of using optically guided 3D ultrasound for IGRT. He noted that ultrasound imaging can be used in combination with intermittent (say, weekly) cone-beam CT scans to minimize any uncertainties in the ultrasound-based alignment, while enabling accurate daily guidance with a large reduction in cumulative dose.

In a slight twist, Tomé actually suggested that none of the technologies in the debate are actually the future of IGRT. What's really needed, he explained, is a means by which to assess metabolic changes during the therapy itself - a scheme he dubbed image-guided treatment. "I can't say that ultrasound is the future of IGRT on its own, but it will play a key role, in conjunction with kV or MV CT," he concluded.

Jan Lagendijk, from the University Medical Center Utrecht in the Netherlands, proposed a novel scheme in which the treatment machine is fully integrated with an MR scanner, enabling precise soft-tissue visualization for treatment guidance and verification.

A key benefit of this technique is its ability to reduce the required margins and minimize normal tissue complications. "You need imaging during the treatment itself, and the only way to do this is with MRI," he declared somewhat controversially. Lagendijk brushed off the criticism from his fellow panellists that such a system doesn't actually exist yet, stating that it will be developed "quicker than expected".

Finally, Kristy Brock of the Princess Margaret Hospital in Canada (Toronto, ON) argued that the future of IGRT lies not in any one imaging modality, but in the use of deformable modelling to combine diagnostic-quality images with daily image guidance. "All these are great imaging technologies but we need to integrate them together," she explained.

And the winner? It was a resounding victory for Brock, proving perhaps that the debate is actually still to be resolved - or maybe never will be. It's likely that all of the above technologies will continue to be employed, and will be further developed and enhanced. As Brock said: "The future of IGRT lies not one of these modalities, but in all of them."

17.28 Tuesday CT: For many of the vendors exhibiting at the AAPM trade show, brachytherapy was the name of the game. For starters, medical device company Nucletron (Columbia, MD) was showcasing its latest brachytherapy offering - the microSelectron Digital afterloader.

The afterloader offers a choice of six, 18 and 30 channels, as well as the ability to perform both high-dose-rate and pulsed-dose-rate brachytherapy. "It is new to have both treatment types in the same system," Nucletron's Tom Pollatz told me. The microSelectron Digital's big selling point, however, is the ease with which it can be upgraded.

A user looking to make a low capital investment could purchase a 6-channel system, for example, which is ideal for use in gynaecological procedures. Then, if at some stage in the future the clinic's resources increase, or the clinicians want to treat additional body parts, they can upgrade to an 18- or 30-channel system - enabling treatments such as prostate brachytherapy or interstitial breast brachytherapy.

The upgrade in itself is relatively straightforward, requiring only minimal downtime and staff training. Pollatz says that, unlike the case for some afterloaders, the main unit itself does not need to be changed, protecting the customer's initial investment. It's simply a case of uploading the software key required to use the higher-channel option.

"Our goal is to provide the lowest-cost entry level for a centre to start a brachytherapy programme," said Pollatz. "We're building a scalable brachytherapy treatment solution that our customers can tailor to whatever body site they want to treat."

The microSelectron Digital afterloader is compatible with a wide range of applicators - including those being newly showcased at this year's AAPM meeting, such as North American Scientific's ClearPath (see More from the exhibit hall) and the SAVI from BioLucent (Aliso Viejo, CA).

BioLucent's SAVI is a new breast brachytherapy device for accelerated partial-breast irradiation (APBI) following a lumpectomy. The applicator combines the tissue-sparing dosimetry of interstitial treatment with the single-entry ease of a balloon-based applicator.

The SAVI applicator comprises a bundle of catheters surrounding a central lumen. It's placed into the lumpectomy cavity through a small incision, and the bundle is expanded to form an ellipsoid. The catheters can be individually imaged (some contain markers for easy identification) and then loaded as appropriate to comply with the medical physicist's treatment plan.

"SAVI combines the best of both worlds," Brian Driscoll, BioLucent's director of marketing explained to me. "It offers the benefits of needing just one incision, but with the dosimetry benefits of an interstitial device." The ability to contour the dose also enables the device to perform APBI in areas located close to the heart or skin, which are not suitable for treatment with a balloon-based applicator.

Driscoll explained that the SAVI received FDA approval last July, treated its first patient in November and is now being exhibited for the first time at a trade show. "It's still a controlled launch, but we're getting closer to a full national launch," he added.

17:19 Tuesday CT: At 5.45 this morning (thank goodness for jet lag!), early-rising locals were treated to the unusual sight of a large gathering of shorts-and-T-shirt clad medical physicists, exhibitors and one journalist in Minneapolis' Boom Island Park. Today was the annual AAPM/Gammex 5k run, which each year sees hundreds of delegates braving an early start and punishing heat in search of that elusive personal best.

Heat certainly was a feature of this year's run. The thermometer was showing 75°F as we pounded past, but the humidity made it feel considerably hotter. Our very own runner extraordinaire, Simon Harris, reckoned that this year's temperatures trumped even those suffered by last year's competitors in Orlando, FL. Perhaps this is why, out of approximately 230 people who registered for the run, only 155 actually turned up.

The conditions didn't seem to hamper race winner Tim Szczykutowicz too much. Making his debut at this event, the physics student from the University at Buffalo (New York, NY) completed the 5k in 18 minutes 43 seconds, well ahead of his quickest competition. What's more, rumour has it that this trifling distance didn't tire him out enough, so he planned to run the extra couple of kilometres back to his hotel. medicalphysicsweb's Tami Freeman asked him how it felt to win: "Very good," said Tim.

All in all, the medicalphysicsweb contingent didn't do too badly. Physics in Medicine and Biology publisher Simon Harris came 15th, with a time of 23:30. "Never again," said AAPM meeting regular Simon while cooling down in the park afterwards. "Mind you, I said that after the race last year!" My effort of 27:50 yielded 40th place - making me not only the fifth woman across the line, but also faster than medicalphysicsweb editor Joe McEntee, who competed in the event last year. (That's enough self-congratulatory reporting - JM)

The full results are available at the Gammex booth, and will be put up on the Gammex website shortly.

IBA reveals all

| | Comments (1)

17.47 Monday CT: Early this morning, a crowd was gathering at IBA's booth to find out exactly what the Belgian particle-therapy company has been keeping under wraps. So what was hiding under that cover? IBA's staff dramatically swept the cloth away to reveal...its Universal Nozzle.

It may not look particularly impressive, but the Universal Nozzle is a nifty piece of kit. In simple terms, the nozzle can be used to perform four different types of proton therapy: single scattering, double scattering, uniform scanning and pencil-beam scanning. What this means is that users wanting to perform these different techniques no longer have to build separate treatment rooms for each one.

"The Universal Nozzle is a way of delivering protons that allows you to do scanning and scattering techniques in one room," announced Stephen Sledge, IBA's marketing director.

By the way, if you were there, and you're still wondering what to do with the small green objects that IBA was handing out, just peer into the end - the effect is quite startling.

More content

You can find more content in the blog’s main index or archives.

Alternatively you can browse posts for this category archived by month: